Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention

The University of Texas Health Science Center, Houston · with National Institutes of Health (NIH) · NCT07743645

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 9–19 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
100
US sites recruiting
1
Study start
September 1, 2026
Record last updated
September 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns

Being studied: Psychosocial intervention group

Conditions: Schizophrenia Spectrum Disorders (SSD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and/or parent/legal guardian report and confirmed by a structured interview
  • screening positive for two or more risk factors targeted by the intervention
  • Participants and parent(s)/legal guardian(s) agree to participate
  • psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.

Exclusion Criteria

  • Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview
  • Current or past antipsychotic medication use to specifically treat a psychotic disorder
  • major medical and neurological conditions
  • moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments;
  • current drug or alcohol use that impacts functioning and study engagement;
  • Not able to give assent, permission, or consent.
  • Not able to undergo MRI.

Recruiting US locations

  • The University of Texas Health Science Center at Houston

    Houston, TX 77030

    Site contact: Yizhou Ma, PhD · 713-486-2740 · Yizhou.Ma@uth.tmc.edu

Study contacts (from the official record)

  • Yizhou Ma, PhD · 713-486-2740 · Yizhou.Ma@uth.tmc.edu
  • Oluwabunmi Akindona, BA · 713-486-2740 · Oluwabunmi.Akindona@uth.tmc.edu
Developing Biomarker-Supported Schizophrenia Spectrum Disorder… (NCT07743645) | Bored Studies